Innovating Works

AC Immune

Desconocido
EPND: European platform for neurodegenerative disorders AC IMMUNE SA participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a la...
2021-10-25 - 2026-10-31 | Financiado
ROADMAP: Real world Outcomes across the AD spectrum for better care Multimodal data Access Platform Sofia... AC IMMUNE SA participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage The aim of ROADMAP is to provide the foundation for a Europe-wide real world evidence (RWE) platform in AD by piloting multi-modal data inte...
2016-12-21 - 2018-10-31 | Financiado
EPAD: European Prevention of Alzheimer’s Dementia Consortium AC IMMUNE SA participó en un FP6: Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression...
2015-01-01 - 2019-12-31 | Financiado
TREATPOLYQ: TreatPolyQ Industrial Academic Initial Training Network towards treatment of Polyglutamine Disease... AC IMMUNE SA participó en un FP7: Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD...
Financiado
EPAD: European Prevention of Alzheimer s Dementia Consortium AC IMMUNE SA participó en un FP7: Background: The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progressio...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.